These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10776795)

  • 21. Antigenic, adjuvant and permeability enhancing properties of melittin in mice.
    Kind LS; Ramaika C; Allaway E
    Allergy; 1981 Apr; 36(3):155-60. PubMed ID: 6940463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Onjisaponins, from the root of Polygala tenuifolia Willdenow, as effective adjuvants for nasal influenza and diphtheria-pertussis-tetanus vaccines.
    Nagai T; Suzuki Y; Kiyohara H; Susa E; Kato T; Nagamine T; Hagiwara Y; Tamura S; Yabe T; Aizawa C; Yamada H
    Vaccine; 2001 Sep; 19(32):4824-34. PubMed ID: 11535335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipopeptides containing 2-(palmitoylamino)-6,7-bis(palmitoyloxy) heptanoic acid: synthesis, stereospecific stimulation of B-lymphocytes and macrophages, and adjuvanticity in vivo and in vitro.
    Metzger J; Jung G; Bessler WG; Hoffmann P; Strecker M; Lieberknecht A; Schmidt U
    J Med Chem; 1991 Jul; 34(7):1969-74. PubMed ID: 2066969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant.
    BenMohamed L; Belkaid Y; Loing E; Brahimi K; Gras-Masse H; Druilhe P
    Eur J Immunol; 2002 Aug; 32(8):2274-81. PubMed ID: 12209640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis of thiol-reactive lipopeptide adjuvants. Incorporation into liposomes and study of their mitogenic effect on mouse splenocytes.
    Roth A; Espuelas S; Thumann C; Frisch B; Schuber F
    Bioconjug Chem; 2004; 15(3):541-53. PubMed ID: 15149182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bacterial cell wall components as immunomodulators--I. Lipopeptides as adjuvants for parenteral and oral immunization.
    Bessler WG; Heinevetter L; Wiesmüller KH; Jung G; Baier W; Huber M; Lorenz AR; Esche UV; Mittenbühler K; Hoffmann P
    Int J Immunopharmacol; 1997; 19(9-10):547-50. PubMed ID: 9637352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo.
    Porgador A; Staats HF; Faiola B; Gilboa E; Palker TJ
    J Immunol; 1997 Jan; 158(2):834-41. PubMed ID: 8993001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The mucosal adjuvant macrophage-activating lipopeptide-2 directly stimulates B lymphocytes via the TLR2 without the need of accessory cells.
    Borsutzky S; Kretschmer K; Becker PD; Mühlradt PF; Kirschning CJ; Weiss S; Guzmán CA
    J Immunol; 2005 May; 174(10):6308-13. PubMed ID: 15879130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
    Goonetilleke NP; McShane H; Hannan CM; Anderson RJ; Brookes RH; Hill AV
    J Immunol; 2003 Aug; 171(3):1602-9. PubMed ID: 12874255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intranasal immunization with immunodominant epitope peptides derived from HpaA conjugated with CpG adjuvant protected mice against Helicobacter pylori infection.
    Yang WC; Sun HW; Sun HQ; Yuan HM; Li B; Li HB; Hu J; Yang Y; Zou QM; Guo H; Wu C; Chen L
    Vaccine; 2018 Oct; 36(42):6301-6306. PubMed ID: 30217524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A recombinant P4 protein of Haemophilus influenzae induces specific immune responses biologically active against nasopharyngeal colonization in mice after intranasal immunization.
    Hotomi M; Ikeda Y; Suzumoto M; Yamauchi K; Green BA; Zlotnick G; Billal DS; Shimada J; Fujihara K; Yamanaka N
    Vaccine; 2005 Jan; 23(10):1294-300. PubMed ID: 15652672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mucosal and systemic immune responses to measles virus haemagglutinin in mice immunized with a recombinant vaccinia virus.
    Etchart N; Wild F; Kaiserlian D
    J Gen Virol; 1996 Oct; 77 ( Pt 10)():2471-8. PubMed ID: 8887480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunostimulant activity of a novel lipopeptide and its protective action against Leishmania donovani.
    Puri A; Rizvi SY; Haq W; Guru PY; Kundu B; Saxena RP; Shukla R; Mathur KB; Saxena KC
    Immunopharmacol Immunotoxicol; 1993 Nov; 15(5):539-56. PubMed ID: 8301018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant is required when using Env lipopeptide construct to induce HIV type 1-specific neutralizing antibody responses in mice in vivo.
    Sauzet JP; Moog C; Krivine A; Martinon F; Bossus M; Gras-Masse H; Tartar A; Guillet JG; Gomard E
    AIDS Res Hum Retroviruses; 1998 Jul; 14(10):901-9. PubMed ID: 9671219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant virus-like particles of a norovirus (genogroup II strain) administered intranasally and orally with mucosal adjuvants LT and LT(R192G) in BALB/c mice induce specific humoral and cellular Th1/Th2-like immune responses.
    Nicollier-Jamot B; Ogier A; Piroth L; Pothier P; Kohli E
    Vaccine; 2004 Mar; 22(9-10):1079-86. PubMed ID: 15003634
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein.
    Tamura S; Miyata K; Matsuo K; Asanuma H; Takahashi H; Nakajima K; Suzuki Y; Aizawa C; Kurata T
    J Immunol; 1996 May; 156(10):3892-900. PubMed ID: 8621928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities.
    Sloat BR; Cui Z
    Pharm Res; 2006 Jun; 23(6):1217-26. PubMed ID: 16718616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen.
    Mizuno D; Ide-Kurihara M; Ichinomiya T; Kubo I; Kido H
    J Immunol; 2006 Jan; 176(2):1122-30. PubMed ID: 16394001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surfactant protein C is an essential constituent for mucosal adjuvanticity of Surfacten, acting as an antigen delivery vehicle and inducing both local and systemic immunity.
    Mizuno D; Kimoto T; Takei T; Fukuta A; Shinahara W; Takahashi E; Yano M; Kido H
    Vaccine; 2011 Jul; 29(33):5368-78. PubMed ID: 21669246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.